Dual-targeted hit identification using pharmacophore screening

Mycobacterium tuberculosis infection remains a major cause of global morbidity and mortality due to the increase of antibiotics resistance. Dual/multi-target drug discovery is a promising approach to overcome bacterial resistance. In this study, we built ligand-based pharmacophore models and performed pharmacophore screening in order to identify hit compounds targeting simultaneously two enzymes—M. tuberculosis leucyl-tRNA synthetase (LeuRS) and methionyl-tRNA synthetase (MetRS). In vitro aminoacylation assay revealed five compounds from different chemical classes inhibiting both enzymes. Among them the most active compound—3-(3-chloro-4-methoxy-phenyl)-5-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-3H-[1,2,3]triazol-4-ylamine (1) inhibits mycobacterial LeuRS and MetRS with IC50 values of 13 µM and 13.8 µM, respectively. Molecular modeling study indicated that compound 1 has similar binding mode with the active sites of both aminoacyl-tRNA synthetases and can be valuable compound for further chemical optimization in order to find promising antituberculosis agents.

[1]  A. K. Forrest,et al.  Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. , 2002, Journal of medicinal chemistry.

[2]  Frederick R. C. Simeons,et al.  University of Dundee Chemical Validation of Methionyl tRNA Synthetase ( MetRS ) as a Druggable Target in Leishmania donovani , 2017 .

[3]  Patricia Saenz-Méndez,et al.  Exploring Polypharmacology in Drug Design. , 2018, Methods in molecular biology.

[4]  A. Jirgensons,et al.  Targeting Multiple Aminoacyl-tRNA Synthetases Overcomes the Resistance Liabilities Associated with Antibacterial Inhibitors Acting on a Single Such Enzyme , 2016, Antimicrobial Agents and Chemotherapy.

[5]  Awanish Kumar,et al.  Aminoacyl-tRNA synthetases: Structure, function, and drug discovery. , 2018, International journal of biological macromolecules.

[6]  Meitian Wang,et al.  Structural characterization of free-state and product-state Mycobacterium tuberculosis methionyl-tRNA synthetase reveals an induced-fit ligand-recognition mechanism , 2018, IUCrJ.

[7]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[8]  N. Subbarao,et al.  High Throughput Virtual Screening to Identify Novel natural product Inhibitors for MethionyltRNA-Synthetase of Brucella melitensis , 2017, Bioinformation.

[9]  Hong Sun,et al.  Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases , 2014, Journal of medicinal chemistry.

[10]  Yufang Xu,et al.  Rationally designed multitarget anticancer agents. , 2013, Current medicinal chemistry.

[11]  Angelo Carotti,et al.  Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer's Disease , 2015, J. Chem. Inf. Model..

[12]  Targeting methionyl tRNA synthetase: design, synthesis and antibacterial activity against Clostridium difficile of novel 3-biaryl-N-benzylpropan-1-amine derivatives , 2016, Journal of enzyme inhibition and medicinal chemistry.

[13]  S. Sakkiah,et al.  An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes , 2013, PloS one.

[14]  F. Dean,et al.  Identification and Characterization of a Chemical Compound that Inhibits Methionyl-tRNA Synthetase from Pseudomonas aeruginosa. , 2017, Current drug discovery technologies.

[15]  F. Buckner,et al.  The crystal structure of the drug target Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with a catalytic intermediate. , 2018, Acta crystallographica. Section F, Structural biology communications.

[16]  David Barros,et al.  Discovery of a Potent and Speci fi c M . tuberculosis Leucyl-tRNA Synthetase Inhibitor : ( S ) ‐ 3-( Aminomethyl ) , 2017 .

[17]  D. Söll,et al.  Drugging tRNA aminoacylation , 2018, RNA biology.

[18]  O. P. Kovalenko,et al.  Discovery of potent anti-tuberculosis agents targeting leucyl-tRNA synthetase. , 2016, Bioorganic & medicinal chemistry.

[19]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[20]  S. M. Fayaz,et al.  Ensembling and filtering: an effective and rapid in silico multitarget drug-design strategy to identify RIPK1 and RIPK3 inhibitors , 2015, Journal of Molecular Modeling.

[21]  T. Jarvis,et al.  Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study , 2017, Antimicrobial Agents and Chemotherapy.

[22]  Ruth Nussinov,et al.  Novel Approach for Efficient Pharmacophore-Based Virtual Screening: Method and Applications , 2009, J. Chem. Inf. Model..

[23]  Gisbert Schneider,et al.  Design of Natural‐Product‐Inspired Multitarget Ligands by Machine Learning , 2019, ChemMedChem.

[24]  C. Francklyn,et al.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics , 2019, The Journal of Biological Chemistry.

[25]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[26]  M. Yogavel,et al.  Inhibition of Protein Synthesis and Malaria Parasite Development by Drug Targeting of Methionyl-tRNA Synthetases , 2015, Antimicrobial Agents and Chemotherapy.

[27]  V. Poroikov,et al.  A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis$ , 2017, SAR and QSAR in environmental research.

[28]  M. Chun,et al.  Methionyl adenylate analogues as inhibitors of methionyl-tRNA synthetase. , 1999, Bioorganic & medicinal chemistry letters.

[29]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[30]  Alessandro Pedretti,et al.  VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming , 2004, J. Comput. Aided Mol. Des..

[31]  O. P. Kovalenko,et al.  Identification of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) inhibitors among the derivatives of 5-phenylamino-2H-[1,2,4]triazin-3-one , 2016, Journal of enzyme inhibition and medicinal chemistry.

[32]  O. H. Griffith,et al.  A robotics-based automated assay for inorganic and organic phosphates. , 1999, Analytical biochemistry.

[33]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[34]  F. Buckner,et al.  Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites , 2015, Antimicrobial Agents and Chemotherapy.

[35]  F. Buckner,et al.  Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections , 2017, Antimicrobial Agents and Chemotherapy.

[36]  Sunghoon Kim,et al.  Aminoacyl-tRNA synthetases as therapeutic targets , 2019, Nature Reviews Drug Discovery.

[37]  F. Buckner,et al.  Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors. , 2017, Bioorganic & medicinal chemistry letters.